Intestinal absorption mechanisms of ginsenoside Rh2: Stereoselectivity and involvement of ABC transporters

Xenobiotica

Volumn 40, Issue 9, 2010, Pages 602-612

  Gu, Y ^a,b   Wang, G J ^a   Wu, X L ^a   Zheng, Y T ^a,c   Zhang, J W ^a   Ai, H ^a   Sun, J G ^a   Jia, Y W ^a,d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Hutchison Medipharma Ltd   (China)

^c FUDAN UNIVERSITY   (China)

^d WANNAN MEDICAL COLLEGE   (China)

Author keywords

ABC transporters; Caco 2 cells; Ginsenoside Rh2; Intestinal Absorption; Stereoselectivity; Transport

Indexed keywords

2,4 DINITROPHENOL; ABC TRANSPORTER; CITRATE SODIUM; CYCLOSPORIN; DEOXYCHOLATE SODIUM; DODECYL SULFATE SODIUM; GINSENOSIDE RH 2; PROBENECID; QUERCETIN;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; INTERNALIZATION; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; ISOMER; MEMBRANE TRANSPORT; MONOLAYER CULTURE; NONHUMAN; PROTEIN FUNCTION; RAT; STEREOCHEMISTRY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL SURVIVAL; DRUG STABILITY; EPITHELIAL CELLS; GINSENOSIDES; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; PERFUSION; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TEMPERATURE; TIME FACTORS;

RATTUS;

EID: 77955607007     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.500744     Document Type: Article

References (57)

1. Artursson P, Karlsson J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
2. Attele AS, Wu JA, Yuan CS. (1999). Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58:1685-1693.
3. Bae EA, Han MJ, Shin YW, Kim DH. (2006). Inhibitory effects of Korean red ginseng and its genuine constituents ginseno- sides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models. Biol Pharm Bull 29:1862-1867.
4. Balakrishnan A, Polli JE. (2006). Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 3:223-230.
5. Brocks DR. (2006). Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm Drug Dispos 27:387-406.
6. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. (2006). Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 3:87-93.
7. Cheng CC, Yang SM, Huang CY, Chen JC, Chang WM, Hsu SL. (2005). Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol 55:531-540.
8. Cogburn JN, Donovan MG, Schasteen CS. (1991). A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res 8:210-216.
9. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
10. Farraj NF, Davis SS, Parr GD, Stevens HNE. (1988). Absorption of progabide from aqueous solutions in a modified recirculating rat intestinal perfusion system. Int J Pharm, 43, 93-100.
11. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT. (2001). A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18:171-176.
12. Gu Y, Wang G, Sun J, Xie H, Jia Y. (2006a). Development of a sensitive LC-ESI-MS assay for 20(R)-ginsenoside Rh2 and its pharmacokinetic application in dogs: A case for the influence of microniza- tion on traditional Chinese medicine. Int J Mass Spectrom, 252, 11-19.
13. Gu Y, Wang GJ, Sun JG, Jia YW, Xie HT, Wang W. (2006b). Quantitative determination of ginsenoside Rh2 in rat biosamples by liquid chromatography electrospray ionization mass spectrometry. Anal Bioanal Chem 386:2043-2053.
14. Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, Xu MJ, Lv T, Zheng YT, Sai Y. (2009). Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol 47:2257-2268.
15. Gumbiner B. (1987). Structure, biochemistry, and assembly of epithelial tight junctions. Am J Physiol 253:C749-C758.
16. Ham YM, Chun KH, Choi JS, Kim DH, Lee SK. (2003). SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis. Biochem Biophys Res Commun 304:358-364.
17. Han M, Sha X, Wu Y, Fang X. (2006). Oral absorption of ginseno- side Rb1 using in vitro and in vivo models. Planta Med 72: 398-404.
18. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS. (2003). Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 310:222-227.
19. Hutt AJ. (2007). Chirality and pharmacokinetics: an area of neglected dimensionality? Drug Metabol Drug Interact 22:79-112.
20. Ikegawa T, Ohtani H, Koyabu N, Juichi M, Iwase Y, Ito C, Furukawa H, Naito M, Tsuruo T, Sawada Y. (2002). Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 177: 89-93.
21. Jeong SM, Lee JH, Kim JH, Lee BH, Yoon IS, Lee JH, Kim DH, Rhim H, Kim Y, Nah SY. (2004). Stereospecificity of ginsenoside Rg3 action on ion channels. Mol Cells 18:383-389.
22. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, Bush JA, Li G. (2004). Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82:431-437.
23. Jin J, Shahi S, Kang HK, van Veen HW, Fan TP. (2006). Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345:1308-1314.
24. Kang DI, Lee JY, Yang JY, Jeong SM, Lee JH, Nah SY, Kim Y. (2005). Evidence that the tertiary structure of 20(S)-ginsenoside Rg(3) with tight hydrophobic packing near the chiral center is important for Na(+) channel regulation. Biochem Biophys Res Commun 333:1194-1201.
25. Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, Nagata I. (1991). Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 2:63-67.
26. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T. (1983). [Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra]. Yakugaku Zasshi 103:612-622.
27. Krishnamurthy P, Schuetz JD. (2006). Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381-410.
28. Lai DM, Tu YK, Liu IM, Chen PF, Cheng JT. (2006). Mediation of beta- endorphin by ginsenoside Rh2 to lower plasma glucose in strep - tozotocin-induced diabetic rats. Planta Med 72:9-13.
29. Lee HU, Bae EA, Han MJ, Kim DH. (2005). Hepatoprotective effect of 20(S)-ginsenosides Rg3 and its metabolite 20(S)-ginsenoside Rh2 on tert-butyl hydroperoxide-induced liver injury. Biol Pharm Bull 28:1992-1994.
30. Lee E, Kim S, Chung KC, Choo MK, Kim DH, Nam G, Rhim H. (2006). 20(S)-ginsenoside Rh2, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons. Eur J Pharmacol 536:69-77.
31. Liang F, Hua JX. (2005). Absorption profiles of sanchinoside R1 and ginsenoside Rg1 in the rat intestine. Eur J Drug Metab Pharmacokinet 30:261-268.
32. Liu J, Shiono J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. (2009). 20®-ginsenoside Rh2, not 20(S), is a selective osteoclastgen- esis inhibitor without any cytotoxicity. Bioorg Med Chem Lett 19:3320-3323.
33. Liu ZQ, Luo XY, Liu GZ, Chen YP, Wang ZC, Sun YX. (2003). In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J Agric Food Chem 51:2555-2558.
34. Martin GP, Marriott C, Kellaway IW. (1978). Direct effect of bile salts and phospholipids on the physical properties of mucus. Gut 19:103-107.
35. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
36. Muranishi S. (1990). Absorption enhancers. Crit Rev Ther Drug Carrier Syst 7:1-33.
37. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I, Shinomiya N. (1998). Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 89:733-740.
38. Oostendorp RL, Beijnen JH, Schellens JH. (2009). The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 35:137-147.
39. Park EK, Choo MK, Kim EJ, Han MJ, Kim DH. (2003). Antiallergic activity of ginsenoside Rh2. Biol Pharm Bull 26:1581-1584.
40. Park EK, Choo MK, Oh JK, Ryu JH, Kim DH. (2004). Ginsenoside Rh2 reduces ischemic brain injury in rats. Biol Pharm Bull 27:433-436.
41. Pitelka DR, Taggart BN, Hamamoto ST. (1983). Effects of extracellular calcium depletion on membrane topography and occluding junctions of mammary epithelial cells in culture. J Cell Biol 96:613-624.
42. Popovich DG, Kitts DD. (2004a). Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2. Can J Physiol Pharmacol 82:183-190.
43. Popovich DG, Kitts DD. (2004b). Mechanistic studies on protopanaxa- diol, Rh2, and ginseng (Panax quinquefolius) extract induced cytotoxicity in intestinal Caco-2 cells. J Biochem Mol Toxicol 18:143-149.
44. Rubas W, Jezyk N, Grass GM. (1993). Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10:113-118.
45. Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M. (1997). Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J Pharm Sci 86:779-785.
46. Sakai M, Imai T, Ohtake H, Otagiri M. (1998). Cytotoxicity of absorption enhancers in Caco-2 cell monolayers. J Pharm Pharmacol 50:1101-1108.
47. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T. (2009). Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 67:535-540.
48. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. (2006). Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299.
49. Shinohara Y, Yoshikawa K, Terada H. (1990). Effect of the weakly acidic uncoupler 2,4-dinitrophenol and dimethyl sulfoxide on the coordination of Mg2+ with ATP. Possible mechanism of activation of the isolated F1-ATPase by 2,4-dinitrophenol. Biophys Chem 36:201-208.
50. Tang F, Horie K, Borchardt RT. (2002). Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765-772. (Pubitemid 34686734)
51. Varma MV, Perumal OP, Panchagnula R. (2006). Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol 10:367-373.
52. Waldeck B. (2003). Three-dimensional pharmacology, a subject ranging from ignorance to overstatements. Pharmacol Toxicol 93:203-210.
53. Xie HT, Wang GJ, Chen M, Jiang XL, Li H, Lv H, Huang CR, Wang R, Roberts M. (2005). Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull 28:383-386.
54. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES. (2006). Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 175:1926-1931.
55. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. (2000). Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204.
56. Yao HM, Chiou WL. (2006). The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322:79-86.
57. Zhang S, Yang X, Morris ME. (2004). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216. (Pubitemid 38543491)